title: Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure.
authors.forename: S
authors.initials: S
authors.lastname: Hanon
authors.forename: P
authors.initials: P
authors.lastname: Vijayaraman
authors.forename: E H
authors.initials: EH
authors.lastname: Sonnenblick
authors.forename: T H
authors.initials: TH
authors.lastname: Le Jemtel
mesh_terms: D000804:Angiotensin II / Q000096:biosynthesis*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000378:metabolism*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II